



Studien & Reviews

Auf den folgenden Seiten finden Sie eine von uns zusammengestellte Auflistung publizierter Studien und Reviews.

SIE HABEN FRAGEN?

Bei aufkommenden Fragen stehen wir Ihnen gerne zur Verfügung

Montag von 13:00 bis 19:00 Uhr,

Dienstag von 10:00 bis 13:00 und 14:30 bis 18:00 Uhr,

Mittwoch von 10:00 bis 13:00 und 14:30 bis 19:00 Uhr,

Donnerstag von 13:00 bis 18:00 Uhr und

Freitag von 10:00 bis 15:00 Uhr

unter nachfolgender Telefonnummer:

+43 660 / 161 40 30

STUDIEN & REVIEWS

Mehrere publizierte Studien und Reviews zeigten, dass die Hormontherapie nach Brustkrebs zu keiner erhöhten Inzidenz von Rezidiven führte.



Di Saja et al. 1995. „Replacement Therapy for Breast Cancer Survivors“.

Chang KJ. „Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo“ Fertil Steril. 1995 Apr; 63(4):785-91.

Braendle W. Division of Gynecological Endocrinology and Reproductive Medicine, University Hospital, Hamburg Eppendorf, Germany. „Hormone replacement therapy in women with breast cancer“.
Anticancer Res. 1998 May-Jun; 18(3C):2253-5.

Schmidt M, Renner C, Löffler G. „Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts“.
J Endocrinol. 1998 Sep; 158(3):401-7.

Formby B, Wiley TS. „Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53“.
Ann Clin Lab Sci. 1998 Nov-Dec; 28(6): 360-9.

Brewster WR, DiSaia PJ, Grosen EA, McGonigle KF, Kuykendall JL, Creasman WT. Division of Gynecologic Oncology, University of California Irvine Medical Center, Orange 92868, USA. „An experience with estrogen replacement therapy in breast cancer survivors“.
Int J Fertil Womens Med. 1999 Jun-Aug; 44(4):186-92.

DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H. „Breast cancer survival and hormone replacement therapy: a cohort analysis“.
Am J Clin Oncol. 2000 Dec; 23(6):541-5

Peters GN, Fodera T, Sabol J, Jones S, Euhus D. The Center for Breast Care, The University of Texas Southwestern Medical Center at Dallas, 75390-9161, USA. „Estrogen replacement therapy after breast cancer: a 12-year follow-up“.
Ann Surg Oncol. 2001 Dec; 8(10):828-32.

Beckmann MW, Jap D, Djahansouzi S, Nestle-Krämling C, Kuschel B, Dall P, Brumm C, Bender HG. „Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates“.
Oncology. 2001; 60(3):199-206.

Siegelmann-Danieli N, Ron I, Kaufman B, Uzieli B, Karminsky N, Inbar M; Israeli Society for Clinical Oncology and Radiotherapy. „Hormone replacement therapy in breast cancer survivors: the Israeli Society for Clinical Oncology and Radiotherapy policy letter“.
Harefuah. 2002 Nov; 141(11):994-6, 1008.

Levgur M. Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY 11219, USA
„Hormone therapy for women after breast cancer: a review“.
J Reprod Med. 2004 Jul; 49(7):510-26.

Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L, Burdakin JH. Department of Medicine, William Beaumont Hospital, Royal Oak-Troy, MI 48073, USA. „Estrogen replacement therapy in breast cancer survivors: a matched- controlled series“. *Menopause*. 2003 Jul-Aug;10(4):277-85.

Batur P, Blixen CE, Moore HC, Thacker HL, Xu M. Department of Internal Medicine, Section of Women's Health Cleveland Clinic Foundation, Crown Centre II, Independence, OH 44131, USA. baturp@ccf.org „Menopausal hormone therapy (HT) in patients with breast cancer“. *Maturitas*. 2006 Jan 20;53(2):123-32.

Xydakis AM, Sakkas EG, Mastorakos G. „Hormone replacement therapy in breast cancer survivors“. *Ann N Y Acad Sci*. 2006 Dec; 1092:349-60.

Angela Ives, doctoral scholar,1 Christobel Saunders, professor of surgical oncology,1 Max Bulsara, research fellow, 2 and James Semmens, professor of health services research3. „Pregnancy after breast cancer: population based study“. *BMJ*. 2007 Jan 27; 334(7586): 194.

William T. Creasman, MD and Philip J. Disaia, MD. „Hormone Replacement and Breast Cancer Risk: Reconsidering the Data ‘Natural’ Hormone Replacement and Breast Cancer Risk: Evidence for Safety and Efficacy“. November 12, 2009 | Breast Cancer, *Oncology Journal*.

Alina Vrieling, Rebecca Hein, Sascha Abbas, Andreas Schneeweiss, Dieter Flesch-Janys and Jenny Chang-Claude. „Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study“. *Breast Cancer Res*. 2011; 13(4): R74. Published online 2011 Jul 26.

Chen CC, Hardy DB, Mendelson CR. „Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1)“. *J Biol Chem*. 2011 Dec 16;286(50): 43091-102.

Badwe R, et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. *J Clin Oncol*. 2011; 29:2845-2851.

Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E. „Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial“. *Eur J Cancer*. 2013 Jan;49(1):52-9. doi: 10.1016/j.ejca.2012.07.003 Epub 2012 Aug 11.

Y Kim and Y Je. „Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis“. *Br J Cancer*. 2014 May 27; 110(11): 2772-2784.

Hisham M et al. „Progesterone receptor modulates estrogen receptor- α action in breast cancer“. *Nature*. 2015 July 16; 523(7560): 313-317.

Nooshinfar E, Safaroghli-Azar A, Bashash D, Akbari ME. „Melatonin, an inhibitory agent in breast cancer“. *Breast Cancer*. 2016 Mar 26.



DR. ARMANDO FARMINI
Wahlarztordination
Facharzt für Gynäkologie & Geburtshilfe
Senologie · Bioidente Hormontherapie
Belegarzt Privatklinik
Wehrle-Diakonissen Salzburg

Ernest-Thun-Straße 12
am Max-Ott-Platz
A-5020 Salzburg
T +43 660 / 161 40 30
E office@drfarmini.com
www.drfarmini.com

Ordinationszeiten:

Mo 13:00 - 19:00
Di 10:00 - 13:00 14:30 - 18:00
Mi 10:00 - 13:00 14:30 - 19:00
Do 13:00 - 18:00
Fr 10:00 - 15:00